BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Nishida N, Kudo M. Immune Phenotype and Immune Checkpoint Inhibitors for the Treatment of Human Hepatocellular Carcinoma. Cancers (Basel) 2020;12:E1274. [PMID: 32443599 DOI: 10.3390/cancers12051274] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 2.5] [Reference Citation Analysis]
Number Citing Articles
1 Morita M, Nishida N, Sakai K, Aoki T, Chishina H, Takita M, Ida H, Hagiwara S, Minami Y, Ueshima K, Nishio K, Kobayashi Y, Kakimi K, Kudo M. Immunological Microenvironment Predicts the Survival of the Patients with Hepatocellular Carcinoma Treated with Anti-PD-1 Antibody. Liver Cancer 2021;10:380-93. [PMID: 34414125 DOI: 10.1159/000516899] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
2 Nishida N. Long-term prognosis and management of hepatocellular carcinoma after curative treatment. Clin Mol Hepatol 2020;26:480-3. [PMID: 32951413 DOI: 10.3350/cmh.2020.0208] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
3 Shrestha R, Bridle KR, Crawford DHG, Jayachandran A. Immune checkpoint molecules are regulated by transforming growth factor (TGF)-β1-induced epithelial-to-mesenchymal transition in hepatocellular carcinoma. Int J Med Sci 2021;18:2466-79. [PMID: 34104078 DOI: 10.7150/ijms.54239] [Reference Citation Analysis]
4 Yao M, Yang JL, Wang DF, Wang L, Chen Y, Yao DF. Encouraging specific biomarkers-based therapeutic strategies for hepatocellular carcinoma. World J Clin Cases 2022; 10(11): 3321-3333 [DOI: 10.12998/wjcc.v10.i11.3321] [Reference Citation Analysis]
5 Nishida N. Role of Oncogenic Pathways on the Cancer Immunosuppressive Microenvironment and Its Clinical Implications in Hepatocellular Carcinoma. Cancers (Basel) 2021;13:3666. [PMID: 34359568 DOI: 10.3390/cancers13153666] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
6 Nishida N. Role of Oncogenic Pathways on the Cancer Immunosuppressive Microenvironment and Its Clinical Implications in Hepatocellular Carcinoma. Cancers (Basel) 2021;13:3666. [PMID: 34359568 DOI: 10.3390/cancers13153666] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
7 Huang C, Zhang C, Sheng J, Wang D, Zhao Y, Qian L, Xie L, Meng Z. Identification and Validation of a Tumor Microenvironment-Related Gene Signature in Hepatocellular Carcinoma Prognosis. Front Genet 2021;12:717319. [PMID: 34899826 DOI: 10.3389/fgene.2021.717319] [Reference Citation Analysis]
8 Chen W, Gao C, Shen J, Yao L, Liang X, Chen Z. The expression and prognostic value of REXO4 in hepatocellular carcinoma. J Gastrointest Oncol 2021;12:1704-17. [PMID: 34532121 DOI: 10.21037/jgo-21-98] [Reference Citation Analysis]
9 Peng Y, Liu C, Li M, Li W, Zhang M, Jiang X, Chang Y, Liu L, Wang F, Zhao Q. Identification of a prognostic and therapeutic immune signature associated with hepatocellular carcinoma. Cancer Cell Int 2021;21:98. [PMID: 33568167 DOI: 10.1186/s12935-021-01792-4] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
10 Yang F, Deng K, Zheng H, Liu Z, Zheng Y. Progress of targeted and immunotherapy for hepatocellular carcinoma and the application of next-generation sequencing. Annals of Hepatology 2022. [DOI: 10.1016/j.aohep.2022.100677] [Reference Citation Analysis]
11 Gao C, Shen J, Chen W, Yao L, Liang X, Zhu R, Chen Z. Increased RBM12 expression predicts poor prognosis in hepatocellular carcinoma based on bioinformatics. J Gastrointest Oncol 2021;12:1905-26. [PMID: 34532138 DOI: 10.21037/jgo-21-390] [Reference Citation Analysis]
12 Lei Y, Li X, Huang Q, Zheng X, Liu M. Progress and Challenges of Predictive Biomarkers for Immune Checkpoint Blockade. Front Oncol 2021;11:617335. [PMID: 33777757 DOI: 10.3389/fonc.2021.617335] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]